A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 500 shares of PRLD stock, worth $450. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 400 25.0%
Holding current value
$450
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.07 - $6.37 $33,457 - $102,958
-16,163 Reduced 51.49%
15,225 $31,000
Q2 2024

Aug 14, 2024

BUY
$3.32 - $5.63 $5,288 - $8,968
1,593 Added 5.35%
31,388 $119,000
Q1 2024

May 15, 2024

SELL
$2.68 - $4.84 $175,633 - $317,189
-65,535 Reduced 68.75%
29,795 $141,000
Q4 2023

Feb 14, 2024

SELL
$1.69 - $4.37 $346,062 - $894,849
-204,771 Reduced 68.23%
95,330 $407,000
Q3 2023

Nov 14, 2023

BUY
$2.74 - $4.79 $721,255 - $1.26 Million
263,232 Added 713.97%
300,101 $927,000
Q2 2023

Aug 14, 2023

BUY
$4.45 - $8.12 $164,067 - $299,376
36,869 New
36,869 $165,000
Q4 2022

Feb 14, 2023

BUY
$4.61 - $8.5 $11,515 - $21,233
2,498 Added 15.88%
18,232 $110,000
Q3 2022

Nov 14, 2022

SELL
$5.0 - $8.82 $469,445 - $828,100
-93,889 Reduced 85.65%
15,734 $104,000
Q2 2022

Aug 15, 2022

BUY
$4.0 - $7.55 $234,900 - $443,373
58,725 Added 115.38%
109,623 $572,000
Q1 2022

May 16, 2022

SELL
$6.9 - $13.22 $604,453 - $1.16 Million
-87,602 Reduced 63.25%
50,898 $352,000
Q4 2021

Feb 14, 2022

BUY
$11.89 - $31.74 $1.47 Million - $3.94 Million
124,005 Added 855.5%
138,500 $1.72 Million
Q3 2021

Nov 15, 2021

SELL
$25.78 - $38.65 $128,925 - $193,288
-5,001 Reduced 25.65%
14,495 $453,000
Q1 2021

May 17, 2021

BUY
$39.27 - $91.68 $765,607 - $1.79 Million
19,496 New
19,496 $845,000
Q4 2020

Feb 16, 2021

SELL
$28.81 - $88.94 $3.2 Million - $9.86 Million
-110,915 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$26.2 - $30.13 $2.91 Million - $3.34 Million
110,915 New
110,915 $3.34 Million

Others Institutions Holding PRLD

About Prelude Therapeutics Inc


  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $32.7M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.